We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$72.6M
AUM Growth
+$36.2M
Cap. Flow
+$39.4M
Cap. Flow %
54.35%
Top 10 Hldgs %
38.26%
Holding
170
New
94
Increased
8
Reduced
36
Closed
17

Sector Composition

Rank Sector Weight
1 Energy 48.57%
2 Healthcare 38.33%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARIA
26
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$592K 0.82%
+92,602
New +$519K
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$624M
$588K 0.81%
+64,223
New +$530K
RPTP
28
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$584K 0.8%
+126,869
New +$510K
VNDA icon
29
Vanda Pharmaceuticals
VNDA
$322M
$560K 0.77%
67,021
ENTA icon
30
Enanta Pharmaceuticals
ENTA
$377M
$549K 0.76%
+18,689
New +$520K
AMGN icon
31
Amgen
AMGN
$201B
$546K 0.75%
3,644
WES icon
32
Western Midstream Partners
WES
$19.8B
$546K 0.75%
+15,311
New +$442K
GILD icon
33
Gilead Sciences
GILD
$162B
$534K 0.74%
5,810
BIIB icon
34
Biogen
BIIB
$29.6B
$532K 0.73%
+2,045
New +$540K
PDLI
35
DELISTED
PDL BioPharma, Inc.
PDLI
$528K 0.73%
+158,634
New +$495K
NKTR icon
36
Nektar Therapeutics
NKTR
$2.34B
$526K 0.72%
2,551
SGEN
37
DELISTED
Seagen Inc. Common Stock
SGEN
$510K 0.7%
14,541
CELG
38
DELISTED
Celgene Corp
CELG
$489K 0.67%
4,884
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$11.4B
$487K 0.67%
+5,902
New +$480K
MDCO
40
DELISTED
Medicines Co
MDCO
$487K 0.67%
15,331
PAA icon
41
Plains All American Pipeline
PAA
$17.4B
$478K 0.66%
22,806
-1,931
-8% -$40.6K
CEQP
42
DELISTED
Crestwood Equity Partners LP
CEQP
$477K 0.66%
40,914
+21,334
+109% +$245K
EXEL icon
43
Exelixis
EXEL
$14B
$458K 0.63%
+114,429
New +$484K
XNPT
44
DELISTED
XENOPORT, INC.
XNPT
$458K 0.63%
+101,554
New +$468K
PGNX
45
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$453K 0.62%
103,807
ALXN
46
DELISTED
Alexion Pharmaceuticals
ALXN
$441K 0.61%
3,167
IONS icon
47
Ionis Pharmaceuticals
IONS
$9.23B
$423K 0.58%
10,447
UTHR icon
48
United Therapeutics
UTHR
$26.4B
$409K 0.56%
+3,669
New +$464K
ACOR
49
DELISTED
Acorda Therapeutics
ACOR
$408K 0.56%
+128
New +$531K
VRTX icon
50
Vertex Pharmaceuticals
VRTX
$120B
$400K 0.55%
+5,033
New +$455K

Similar funds

Virtus ETF Advisers's Q1 2016 Portfolio in Review

As of Q1 2016, Virtus ETF Advisers held 170 positions worth $72.6M, up 99% from $36.4M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Virtus ETF Advisers deployed $39.4M of net new capital in Q1 2016, opening 94 new positions and adding to 8 existing holdings. Its largest new stake was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.

By sector, the portfolio is most concentrated in Energy at 49% of assets, up from 27% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Spectra Energy Corp Wi, an estimated $258K trimmed.

  • Virtus ETF Advisers's largest Q1 2016 buy was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.
  • Virtus ETF Advisers added most to Buckeye Partners, L.P. in Q1 2016, an estimated $1.73M increase.
  • Virtus ETF Advisers's biggest Q1 2016 reduction was Spectra Energy Corp Wi, cutting an estimated $258K.
  • Virtus ETF Advisers fully exited Aegerion Pharmaceuticals in Q1 2016, selling an estimated $656K.
  • Virtus ETF Advisers's ten largest holdings make up 38% of its $72.6M portfolio in Q1 2016.
  • Virtus ETF Advisers opened 94 new positions and closed 17 in Q1 2016.
  • Virtus ETF Advisers's portfolio value rose 99% quarter-over-quarter to $72.6M.

Based on Virtus ETF Advisers's 13F filing for Q1 2016, filed 16 May 2016.